Today, the Intellectual Property Committee receives income from one licence agreement based on a patent belonging to Sveinbjörn Gizurarson, Professor at the Faculty of Pharmaceutical Sciences, on a new absorption enhancing agent suitable for mucosal administration, e.g. intranasal. 2013, the pharmaceutical company Upsher-Smith began phase III clinical trials in 10 countries on an antiepileptic based on Sveinbjörn's patent. The drug is administered to patients suffering from serial epileptic seizures, using a nasal spray rather than an injectable solution. Sveinbjörn's invention is currently being considered with regards to other drugs. 

Dr Halldór Þormar and his colleagues Hilmar Hilmarsson and Guðmundur Bergsson developed a technique for producing a water-miscible monacaprin emulsion which kills bacteria that cause infections in humans, e.g. listeria, campylobacter, salmonella, staphylococcus and coliform bacteria. The technique is protected by a European patent. Monocaprin is a natural antimicrobial lipid, produced in particular from coconut oil. All components of the emulsion have E-numbers and are recognised as additives for processed food, such as smoked salmon. Permission has been sought from the European Commission to use the emulsion in unprocessed meat.  

Þú ert að nota: brimir.rhi.hi.is